Meconin is a naturally occurring phthalide found in various plants, including opium poppy (Papaver somniferum) and Corydalis species. It is a precursor to the biosynthesis of morphine and other opium alkaloids. Meconin exhibits a wide range of pharmacological activities, including anti-inflammatory, anti-nociceptive, and antioxidant properties. Its synthesis involves enzymatic reactions starting from reticuline, a key intermediate in alkaloid biosynthesis. Researchers study meconin due to its potential therapeutic applications in treating pain, inflammation, and oxidative stress. It has also been investigated as a possible target for drug development in areas such as cancer and neurodegenerative diseases.'
meconin: a marker for illicit opiate use
ID Source | ID |
---|---|
PubMed CID | 68437 |
CHEMBL ID | 1333869 |
CHEBI ID | 173937 |
SCHEMBL ID | 698750 |
MeSH ID | M0510958 |
Synonym |
---|
6,7-dimethoxy-1(3h)-isobenzofuranone |
6,7-dimethoxy-1,3-dihydro-2-benzofuran-1-one |
CHEBI:173937 |
6,7-dimethoxy-3h-2-benzouran-1-one |
meconin |
NSC35547 , |
1(3h)-isobenzofuranone,7-dimethoxy- |
mekonin |
meconic lactone |
nsc-35547 |
6,7-dimethoxyphthalide |
meconine |
opianyl |
569-31-3 |
phthalide,7-dimethoxy- |
maconine |
DIVK1C_003507 |
AE-641/30608025 |
6,7-dimethoxy-2-benzofuran-1(3h)-one |
smr000386950 |
MLS001049120 |
CDS1_002467 |
CHEMDIV1_018723 |
AKOS001376922 |
6,7-dimethoxy-3h-2-benzofuran-1-one |
FT-0651929 |
HMS640D01 |
NCGC00246213-01 |
6,7-dimethoxyisobenzofuran-1(3h)-one |
nsc 35547 |
unii-mk5r222cg0 |
einecs 209-311-8 |
mk5r222cg0 , |
HMS2267N03 |
FT-0670968 |
meconin [mi] |
SCHEMBL698750 |
AM807365 |
6,7-dimethoxy-3h-isobenzofuran-1-one |
CHEMBL1333869 |
6,7-dimethoxy-3h-1-isobenzofuranone |
mfcd00219354 |
SY020123 |
6,7-dimethoxy 3h-isobenzofuranone |
6,7-dimethoxy-isobenzo-furan-1 (3h)-one |
6,7-dimethoxyisobenzofuran-1 (3h)-one |
phthalide, 6,7-dimethoxy- |
1(3h)-isobenzofuranone, 6,7-dimethoxy- |
AC-25607 |
DTXSID60205433 |
sr-01000388929 |
SR-01000388929-1 |
6,7-dimethoxy-phthalide |
BCP16837 |
CS-0028244 |
AC2115 |
CS-11421 |
STL561453 |
Q27284078 |
HY-W019151 |
EN300-7371095 |
Z234875088 |
Class | Description |
---|---|
2-benzofurans | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 28.1838 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
snurportin-1 | Homo sapiens (human) | Potency | 6.5131 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.7946 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0708 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Alpha-synuclein | Homo sapiens (human) | Potency | 31.6228 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 35.4813 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.67) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |